FMC Colville is a medicare approved dialysis facility center in Colville, Washington and it has 8 dialysis stations. It is located in Stevens county at 147 Garden Homes Dr, Colville, WA, 99114. You can reach out to the office of FMC Colville at (509) 684-3979. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC Colville has the following ownership type - Profit. It was first certified by medicare in June, 2009. The medicare id for this facility is 502557 and it accepts patients under medicare ESRD program.
| Name | FMC Colville |
|---|---|
| Location | 147 Garden Homes Dr, Colville, Washington |
| No. of Dialysis Stations | 8 |
| Medicare ID | 502557 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 147 Garden Homes Dr, Colville, Washington, 99114 | |
| (509) 684-3979 | |
News Archive
Michael Alosco, PhD, associate professor of neurology at Boston University School of Medicine, and Gil Rabinovici, MD, professor of neurology and radiology at the University of California San Francisco have been awarded a two-year, $460,000 grant from the National Institute of Neurological Disorders and Stroke, which is part of the National Institutes of Health.
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.
Eclipsys Corporation®, The Outcomes Company®, today announced that Phoenix Children's Hospital, one of the 10 largest freestanding children's hospitals in the country, has successfully completed an enterprise-wide activation of the company's computerized physician order entry (CPOE) system, Sunrise Acute Care™.
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
› Verified 1 days ago
| NPI Number | 1457500019 |
| Doing Business As | Inland Northwest Renal Care Group Llc |
| Address | 147 Garden Homes Dr. Colville, Washington, 99114 |
| Phone Number | (509) 684-3979 |
News Archive
Michael Alosco, PhD, associate professor of neurology at Boston University School of Medicine, and Gil Rabinovici, MD, professor of neurology and radiology at the University of California San Francisco have been awarded a two-year, $460,000 grant from the National Institute of Neurological Disorders and Stroke, which is part of the National Institutes of Health.
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.
Eclipsys Corporation®, The Outcomes Company®, today announced that Phoenix Children's Hospital, one of the 10 largest freestanding children's hospitals in the country, has successfully completed an enterprise-wide activation of the company's computerized physician order entry (CPOE) system, Sunrise Acute Care™.
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
› Verified 1 days ago
| Dialysis patients with Hemoglobin data | 16 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 13 |
News Archive
Michael Alosco, PhD, associate professor of neurology at Boston University School of Medicine, and Gil Rabinovici, MD, professor of neurology and radiology at the University of California San Francisco have been awarded a two-year, $460,000 grant from the National Institute of Neurological Disorders and Stroke, which is part of the National Institutes of Health.
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.
Eclipsys Corporation®, The Outcomes Company®, today announced that Phoenix Children's Hospital, one of the 10 largest freestanding children's hospitals in the country, has successfully completed an enterprise-wide activation of the company's computerized physician order entry (CPOE) system, Sunrise Acute Care™.
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
› Verified 1 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 26 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 254 |
| Percentage of adult patients getting regular hemodialysis at the center | 100 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Michael Alosco, PhD, associate professor of neurology at Boston University School of Medicine, and Gil Rabinovici, MD, professor of neurology and radiology at the University of California San Francisco have been awarded a two-year, $460,000 grant from the National Institute of Neurological Disorders and Stroke, which is part of the National Institutes of Health.
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.
Eclipsys Corporation®, The Outcomes Company®, today announced that Phoenix Children's Hospital, one of the 10 largest freestanding children's hospitals in the country, has successfully completed an enterprise-wide activation of the company's computerized physician order entry (CPOE) system, Sunrise Acute Care™.
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
› Verified 1 days ago
| Adult patients getting regular peritoneal dialysis at the center | 2 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 22 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Michael Alosco, PhD, associate professor of neurology at Boston University School of Medicine, and Gil Rabinovici, MD, professor of neurology and radiology at the University of California San Francisco have been awarded a two-year, $460,000 grant from the National Institute of Neurological Disorders and Stroke, which is part of the National Institutes of Health.
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.
Eclipsys Corporation®, The Outcomes Company®, today announced that Phoenix Children's Hospital, one of the 10 largest freestanding children's hospitals in the country, has successfully completed an enterprise-wide activation of the company's computerized physician order entry (CPOE) system, Sunrise Acute Care™.
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
› Verified 1 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC Colville with elevated calcium levels.
| Patients with hypercalcemia | 31 |
| Hypercalcemia patient months | 310 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 2 |
| Patients with Serumphosphor | 34 |
| Patients with Serumphosphor less than 3.5 mg/dL | 7 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 29 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 27 |
| Patients with Serumphosphor greater than 7 mg/dL | 10 |
News Archive
Michael Alosco, PhD, associate professor of neurology at Boston University School of Medicine, and Gil Rabinovici, MD, professor of neurology and radiology at the University of California San Francisco have been awarded a two-year, $460,000 grant from the National Institute of Neurological Disorders and Stroke, which is part of the National Institutes of Health.
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.
Eclipsys Corporation®, The Outcomes Company®, today announced that Phoenix Children's Hospital, one of the 10 largest freestanding children's hospitals in the country, has successfully completed an enterprise-wide activation of the company's computerized physician order entry (CPOE) system, Sunrise Acute Care™.
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
› Verified 1 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 34 |
| Patient months included in arterial venous fistula and catheter summaries | 270 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 79 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 3 |
News Archive
Michael Alosco, PhD, associate professor of neurology at Boston University School of Medicine, and Gil Rabinovici, MD, professor of neurology and radiology at the University of California San Francisco have been awarded a two-year, $460,000 grant from the National Institute of Neurological Disorders and Stroke, which is part of the National Institutes of Health.
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.
Eclipsys Corporation®, The Outcomes Company®, today announced that Phoenix Children's Hospital, one of the 10 largest freestanding children's hospitals in the country, has successfully completed an enterprise-wide activation of the company's computerized physician order entry (CPOE) system, Sunrise Acute Care™.
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
› Verified 1 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 35 |
| Hospitalization Rate in facility | 99.9 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 242.9 |
| Hospitalization Rate: Lower Confidence Limit | 44 |
News Archive
Michael Alosco, PhD, associate professor of neurology at Boston University School of Medicine, and Gil Rabinovici, MD, professor of neurology and radiology at the University of California San Francisco have been awarded a two-year, $460,000 grant from the National Institute of Neurological Disorders and Stroke, which is part of the National Institutes of Health.
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.
Eclipsys Corporation®, The Outcomes Company®, today announced that Phoenix Children's Hospital, one of the 10 largest freestanding children's hospitals in the country, has successfully completed an enterprise-wide activation of the company's computerized physician order entry (CPOE) system, Sunrise Acute Care™.
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
› Verified 1 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC Colville were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 16.1 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 39.6 |
| Readmission Rate: Lower Confidence Limit | 3.7 |
News Archive
Michael Alosco, PhD, associate professor of neurology at Boston University School of Medicine, and Gil Rabinovici, MD, professor of neurology and radiology at the University of California San Francisco have been awarded a two-year, $460,000 grant from the National Institute of Neurological Disorders and Stroke, which is part of the National Institutes of Health.
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.
Eclipsys Corporation®, The Outcomes Company®, today announced that Phoenix Children's Hospital, one of the 10 largest freestanding children's hospitals in the country, has successfully completed an enterprise-wide activation of the company's computerized physician order entry (CPOE) system, Sunrise Acute Care™.
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
› Verified 1 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FMC Colville get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .75 (As Expected) |
| SIR: Upper Confidence Limit | 3.71 |
| SIR: Lower Confidence Limit | .04 |
News Archive
Michael Alosco, PhD, associate professor of neurology at Boston University School of Medicine, and Gil Rabinovici, MD, professor of neurology and radiology at the University of California San Francisco have been awarded a two-year, $460,000 grant from the National Institute of Neurological Disorders and Stroke, which is part of the National Institutes of Health.
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.
Eclipsys Corporation®, The Outcomes Company®, today announced that Phoenix Children's Hospital, one of the 10 largest freestanding children's hospitals in the country, has successfully completed an enterprise-wide activation of the company's computerized physician order entry (CPOE) system, Sunrise Acute Care™.
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
› Verified 1 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FMC Colville's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 30 |
| Transfusion Rate in facility | 25.7 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 124.8 |
| Transfusion Rate: Lower Confidence Limit | 6.4 |
News Archive
Michael Alosco, PhD, associate professor of neurology at Boston University School of Medicine, and Gil Rabinovici, MD, professor of neurology and radiology at the University of California San Francisco have been awarded a two-year, $460,000 grant from the National Institute of Neurological Disorders and Stroke, which is part of the National Institutes of Health.
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.
Eclipsys Corporation®, The Outcomes Company®, today announced that Phoenix Children's Hospital, one of the 10 largest freestanding children's hospitals in the country, has successfully completed an enterprise-wide activation of the company's computerized physician order entry (CPOE) system, Sunrise Acute Care™.
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
› Verified 1 days ago
The rate of mortality show you whether patients who were being treated regularly at FMC Colville lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 152 |
| Mortality Rate in facility | 11.8 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 19.1 |
| Mortality Rate: Lower Confidence Limit | 6.7 |
News Archive
Michael Alosco, PhD, associate professor of neurology at Boston University School of Medicine, and Gil Rabinovici, MD, professor of neurology and radiology at the University of California San Francisco have been awarded a two-year, $460,000 grant from the National Institute of Neurological Disorders and Stroke, which is part of the National Institutes of Health.
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.
Eclipsys Corporation®, The Outcomes Company®, today announced that Phoenix Children's Hospital, one of the 10 largest freestanding children's hospitals in the country, has successfully completed an enterprise-wide activation of the company's computerized physician order entry (CPOE) system, Sunrise Acute Care™.
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
› Verified 1 days ago
News Archive
Michael Alosco, PhD, associate professor of neurology at Boston University School of Medicine, and Gil Rabinovici, MD, professor of neurology and radiology at the University of California San Francisco have been awarded a two-year, $460,000 grant from the National Institute of Neurological Disorders and Stroke, which is part of the National Institutes of Health.
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.
Eclipsys Corporation®, The Outcomes Company®, today announced that Phoenix Children's Hospital, one of the 10 largest freestanding children's hospitals in the country, has successfully completed an enterprise-wide activation of the company's computerized physician order entry (CPOE) system, Sunrise Acute Care™.
Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.
› Verified 1 days ago